Combined agonists act synergistically to increase mucociliary clearance in a cystic fibrosis airway model

Nam Soo Joo1*, Hyung-Ju Cho3, Meagan Shinbashi1, Jae Young Choi3, Carlos E. Milla2, John F. Engelhardt4 & Jeffrey J. Wine1*

Mucus clearance, a primary innate defense mechanism of airways, is defective in patients with cystic fibrosis (CF) and CF animals. In previous work, the combination of a low dose of the cholinergic agonist, carbachol with forskolin or a β adrenergic agonist, isoproterenol synergistically increased mucociliary clearance velocity (MCCV) in ferret tracheas. Importantly, the present study shows that synergistic MCCV can also be produced in CF ferrets, with increases ~ 55% of WT. Synergistic MCCV was also produced in pigs. The combined agonists increased MCCV by increasing surface fluid via multiple mechanisms: increased fluid secretion from submucosal glands, increased anion secretion across surface epithelia and decreased Na+ absorption. To avoid bronchoconstriction, the cAMP agonist was applied 30 min before carbachol. This approach to increasing mucus clearance warrants testing for safety and efficacy in humans as a potential therapeutic for muco-obstructive diseases.

Cystic fibrosis (CF) is a multi-organ syndrome of which the most critical clinical phenotype is the propensity for airway mucus obstruction, chronic lung infections, and neutrophilic inflammation. Unless arrested, the resulting tissue damage produces a life-long decline in pulmonary function. CF is caused by loss of function mutations in the gene for an anion channel, CFTR, cystic fibrosis transmembrane conductance regulator, which is important for fluid secretion in the airways. CF airways appear normal at birth, but their airway surface liquid (ASL) is less able to kill bacteria1 and mucus clearance rates are slowed2. Chronic lung infections are the main drivers of declining lung function in humans3,4, and when prevented in CF ferrets with prophylactic antibiotics, a tenfold increase in longevity ensued, in spite of still having a muco-obstructive phenotype with obstruction and inflammation5.

Improving mucociliary clearance velocity (MCCV) in CF airways is a therapeutic goal. Improvements in mucus clearance, sometimes sufficient to show clinical efficacy, have been obtained with inhalation therapies with recombinant human DNase (Pulmozyme)6,7, hypertonic saline8,9, or powdered mannitol10. For most people with CF, the most effective improvements in mucus clearance are provided by small molecules that partially restore CFTR function11,12. For those whose mutations are not treatable with current modulators, or whose lung declines continue despite modulators, additional improvements in mucus clearance could be therapeutic. MCCV is a function of the volume and rheological properties of airway surface liquid (ASL) and ciliary beat frequency (CBF)13. We define ASL as all the liquid on the surface, including both the periciliary layer, where shorter mucins are attached to the cilia14 and the mucus layer containing large gel-forming mucins like MUC5B, which are essential for mucus clearance15.

During experiments to quantify how CFTR and ENaC (the epithelial sodium channel) modulators alter mucociliary clearance in ex vivo ferret tracheas, we discovered that combinations of a β-adrenergic agonist (we used forskolin as a surrogate, but isoproterenol is effective) with a low dose of cholinergic agonist promoted dramatic increases in MCCV that were significantly greater than the sum of the increases produced by either agonist separately16. It was not known if these results would generalize, nor if they could be produced in CF.

Here, we show that such synergistic increases in MCCV can also be produced in pigs and importantly, in CF ferrets. We investigate the potential mechanism that leads to synergistic MCCV by studying the roles of airway submucosal glands, airway surface epithelia, and cilia.

1The Cystic Fibrosis Research Laboratory, Stanford University, Bldg. 420, Main Quad, Stanford, CA 94305-2130, USA. 2Department of Pediatrics, Stanford University, Stanford, CA 94305, USA. 3Department of Otorhinolaryngology, Yonsei University, Seoul, Korea. 4Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. *email: nsjoo@stanford.edu; wine@stanford.edu
Results

Synergistic increases of MCCV in CF ferrets and WT pigs. We define the ‘synergy paradigm’ as the sequential exposure to 30 min of either a CAMP or Ca²⁺ elevating agonist, followed by at least a 30 min exposure to the combined agonists. We used 10 µM forskolin, isoproterenol or formoterol as CAMP agonists, and 0.3 µM carbachol as the Ca²⁺ elevating agonist (all basolateral). In prior work these combinations caused increases in MCCV of ferret tracheas were much greater than the predicted additive effects of the two agonists and approached maximal values.

To determine if synergistic increases of MCCV could be produced in CF ferret tracheas, we tested tracheas from 7 transgenic adult CF ferrets of mixed genotype (see “Methods” section). We divided the 7 CF ferret tracheas into two groups and tested 4 by applying forskolin first and 3 by applying carbachol first, followed by the combined agonists. MCCV (all values are in mm/min) was then measured for 90–150 min and plotted as MCCV vs time and agonist(s) in Fig. 1A. MCCV declined to near zero in the first 30 min without stimulation (Fig. 1A, see figure legend for details). Forskolin produced no increase in MCCV and carbachol produced only a small increase. However, when the agonists were then combined in either order, they produced large, sustained increases in MCCV to ~ 20 mm/min. Averaged data for the last 20 min of each period of basal and single drug treatment and the period from 10 to 80 min after adding the combined agonists are shown as a box and whisker plot in Fig. 1B. MCCV values were: unstimulated: 1.6 ± 1.09 (n = 3); by 10 µM forskolin: 0.18 ± 0.09 (n = 4); by 0.3 µM carbachol: 3.29 ± 2.08 (n = 3), ‘Sum’ is the arithmetic sum of MCCV induced by the two agonists used separately: 3.5 ± 2.07; SR, synergy response by the combined agonists: 19.95 ± 4.12, (P = 0.006 SR vs. Sum). Responses for individual CF ferrets are shown in Supplementary Fig. 1A–G.

Encouraged by these results, we then asked if synergy could be observed in different species. We measured MCCV in tracheas from 2 to 5 days old WT piglets (see “Methods” section for details). Unstimulated MCC velocity was less than 1 mm/min (averaged T10-30 MCCV, 0.93 ± 0.39, n = 8 piglet tracheas) like that of WT ferrets. We divided the 8 piglet tracheas into two groups and tested 4 by applying forskolin first and 4 by applying carbachol first, followed by the combined agonists. Carbachol or forskolin produced only basal increases in MCCV, but the combined agonists produced large, sustained increases in MCCV to 12–17 mm/min regardless of the order of addition (Fig. 1C). Averaged data for the last 20 min of each period of basal and single agonist treatment and the last 50 min of synergy paradigm period are shown as a box and whisker plot in Fig. 1D. Averaged MCCV values were: by 0.3 µM carbachol: 0.91 ± 0.63 to 1.12 ± 0.82 (P = 0.32, Carb vs. Bs/basal, 4 piglets); by 10 µM forskolin: 0.95 ± 0.65 to 2.46 ± 0.68 (P = 0.13, n = 4); sum of individual response (Sum): 3.58 ± 1.06, and by the synergy paradigm (SR): 13.92 ± 0.94.

The box and whisker plots make it clear that the increases in MCCV to the combined agonists were significantly larger for the combined agonists than for the arithmetic sum of the responses for both CF ferrets and WT pigs. Thus, MCCV synergy exists in at least two species and persists, at least in part, after loss of CFTR function. The MCCV of CF ferrets in the synergy condition was 5.7-fold faster than the arithmetically summed responses of agonists used separately, but the value of practical importance is how this compares to WT ferrets. We compared the CF ferret values with those obtained previously from WT ferrets. Forskolin alone, WT versus CF ferret MCCV values were 6.75 ± 0.84 (n = 28) versus 0.18 ± 0.09 (n = 4). For carbachol alone WT versus CF ferret MCCV values were 8.24 ± 0.82 (n = 12) versus 3.29 ± 2.08 (n = 3). For synergistic responses to the combined agonists, WT vs CF MCCV values were 36.24 ± 0.9, (n = 40) versus 19.95 ± 4.12 (n = 7). Thus, compared to WT ferrets, CF ferret responses were ~ 0% for forskolin, ~ 40% for carbachol, and ~ 55% for synergy.

These experiments used forskolin to elevate cAMP. To evaluate a clinically readily available β-adrenergic drug, we measured MCCV in response to 10 µM of the β2-adrenergic receptor agonist formoterol in place of forskolin. We saw comparable synergistic increases in MCCV in pig tracheas (in mm/min): baseline, 0.3 ± 1.0 (n = 12); 10 µM formoterol, 2.4 ± 0.9 (n = 5), 0.3 µM carbachol, 1.3 ± 0.8 (n = 3); and 10.9 ± 0.8 by the combined agonists (n = 7 piglet tracheas) (Fig. 1E,F).

Combined agonists did not induce airway smooth muscle contraction or airway narrowing. The CAMP and Ca²⁺-elevating agonists that increase MCCV also affect airway smooth muscle. Used alone they have opposite effects: Ca²⁺-elevating agonists contract muscles whereas cAMP-elevating agonists relax them. For therapeutic use, the potential for producing unwanted bronchoconstriction with the combined agonists is a safety concern. To determine which effect predominates, we measured airway smooth muscle responses to carbachol ± 10 µM forskolin or formoterol using two different methods: measuring muscle tension and lumen area. Tension of ferret trachealis muscle bundles was measured to increasing carbachol concentrations ± 10 µM forskolin. Forskolin abolished tension increases to 0.3 and 0.6 µM carbachol and greatly reduced responses to higher doses of carbachol (Fig. 2A,B). Lumen area, imaged in thin sliced piglet or ferret tracheal rings, displayed a sustained 20–40% reduction with exposure to 0.3 µM carbachol, but when carbachol was preceded by either forskolin or formoterol, it induced only a transient decrease of 5% or less (Fig. 2C–F). Importantly, this same protective effect was observed in CF ferrets (Fig. 2F).

The velocity of mucus clearance reflects the transportability of mucus and ciliary beat frequency. Transportability is in turn largely determined by hydration/concentration and pH (or bicarbonate content) of the mucus. A major source of upper airway fluid is submucosal glands, and the agonists we used to stimulate MCCV also stimulate submucosal gland secretion. ASL depth and composition are also modified by surface epithelia that secrete and absorb electrolytes/fluid. Indeed, this is the principle means of controlling ASL in epithelia that secrete and absorb electrolytes/fluid. Thus, control of ASL is a means of controlling mucus portability. Finally, ASL pH (or bicarbonate content) is increased by elevating either cAMP or Ca²⁺. The following experiments sought evidence to support or challenge a possible contribution of each of these mechanisms to synergistic increases in MCCV.
Synergistic glandular mucus secretion in WT pigs, WT ferrets, and CF ferrets. We hypothesize that synergistic increases in MCCV rely partly on increased mucus secretion from submucosal glands. This hypothesis arises from evidence that combinations of $[\text{Ca}^{2+}]_i$-elevating and $[\text{cAMP}]_i$-elevating agonists produce synergistically elevated rates of mucus from submucosal glands of humans, pigs, and ferrets. However, in those experiments different specific concentrations of agonists were used. To determine if the same protocols used here produced synergistic increases in secretion from submucosal glands, we measured mucus secretion rates of individual tracheal glands in WT pigs and ferrets and in CF ferrets via time-lapse optical imaging while stimulating them with the same concentrations of agonists and durations of exposure used for MCCV studies. All secretion rates are reported as nanoliters/min/gland.

Figure 1. Synergistic mucus clearance in CF ferret and WT pig tracheas. (A) Time courses of MCCV from CF ferrets in response to 10 µM forskolin (blue open circles, Fsk, $n = 4$), 0.3 µM carbachol (red open squares, Carb, $n = 4$) or the combination (filled symbols). CF ferret genotypes were 5 CFTR<sup>G551D</sup>, one CFTR<sup>∆F/∆F</sup>, and one CFTR<sup>G551D/KO</sup>. (B) Summary data as box and whisker plots. Bs: basal/unstimulated MCCV, Sum: arithmetic sum of MCCV to agonists used separately, SR: synergy to combined agonists. SR was 5.7 times larger than sum, ($P = 0.006, n = 3–7$). (C) MCCV from 2 to 5-day old piglets: same protocol and symbols as for ferrets. (D) Summary data. SR was 3.9 times larger than sum, ($P = 3.8 \times 10^{-5}, n = 4–8$). (E) Responses in pigs to 10 µM formoterol/Fmt (blue circles) instead of forskolin, otherwise same protocol and symbols. (F) Summary data. SR was 3.4 times larger than sum, ($P = 0.005, n = 3–7$).
In WT pig tracheal glands, the average unstimulated secretion rate was in nl/min/gland, (0.21 ± 0.06, 121 glands, 8 pigs, Fig. 3A). The basal rate was significantly increased by each agonist alone and was further increased by their combination in either order. Rates to the combined agonists were significantly larger than the arithmetical sum of their individual responses: additive sum = 1.26 ± 0.19, 7 pigs versus combined agonists = 2.86 ± 0.25 (2.3-fold larger, \( P < 0.01 \), 8 pigs). Data for individual pigs is shown in Fig. 3B for forskolin first and in Fig. 3C for carbachol first. (See also Supplementary Movie 1).

WT Ferrets gave similar results (Fig. 3D–F). In ferret tracheal glands, the average unstimulated secretion rate was ~ zero (0.003 ± 0.001, 67 glands, 7 ferrets, Fig. 3D). It was significantly increased by forskolin (0.26 ± 0.07, 37 glands, 7 ferrets \( P < 0.05 \)) and by carbachol (0.94 ± 0.28, 30 glands, 7 ferrets \( P < 0.05 \)). The secretion rates to the combined agonists were significantly larger than the arithmetical sum of their individual responses (Fig. 3D): overall arithmetic sum = 1.27 ± 0.23 versus 2.46 ± 0.39 for the combined agonists (1.9-fold larger, \( P < 0.05 \), 55–67 glands, 5–7 ferrets. Data for individual WT control ferrets is shown in Fig. 3E for forskolin first and in Fig. 3F for carbachol first.

Importantly, CF ferrets (CFTR\(^{KO/KO}\)) also showed synergistic gland secretion in spite of having no response to forskolin alone. We were able to test only two CF ferrets (Fig. 3G–I). One CF ferret was stimulated first with 10 \( \mu \)M forskolin, the other with 0.3 \( \mu \)M carbachol, and both with the synergy paradigm. Unstimulated secretion rates were ~ zero, as in WT ferrets. Forskolin alone failed to stimulate secretion as expected (0.01, 7 glands), carbachol alone increased the average secretion rate to 0.45 ± 0.16, and the combined agonists increased average rates to 1.23 ± 0.35, 7 glands, and 1.31 ± 0.19, 7 glands. When agonists were combined synergy was seen in both orders of addition. The averaged secretion rate across both ferrets to the combined agonists was 1.27 ± 0.15, which is 2.8 times the arithmetic sum of the two agonists used alone, and about half of the response of WT ferrets of 2.46 ± 0.39\(^{16}\).

To summarize this section, the rates of mucus secretion across both species and including CF ferrets is increased to values beyond the additive sum of the agents used alone, providing circumstantial evidence that gland secretion rates contribute to MCCV in our system.

**Combined agonists stimulate epithelial surface anion secretion and inhibit Na\(^+\) absorption.** The surface epithelia also modify ASL. Figure 4A is a cartoon of the main ion flows controlling ASL depth: anion-mediated fluid secretion increases, and Na\(^+\)-mediated fluid absorption decreases ASL depth. We hypothesize that the combined agonists increase ASL depth and thus MCCV by stimulating secretion and inhibiting absorption (see also Fig. 6). Figure 4B shows our best example of an \( I_{m} \) trace from pig tracheal mucosa stimulated with forskolin followed by carbachol. Forskolin caused a sustained \( I_{m} \) increase with no measurable change in conductance. When 0.3 \( \mu \)M carbachol was then added, it induced a transient \( I_{m} \) increase followed by slow decreases in \( I_{m} \) and conductance, with conductance reduced to 84% of the pre- and immediate post-forskolin value after ~ 30 min. The ENaC inhibitor benzamil (Bz) did not cause further changes in \( I_{m} \) or conductance, suggesting that carbachol completely inhibited ENaC-dependent Na\(^+\) absorption. At this point the epithelium is...
secreting anions, indicated by steep drops in $I_{sc}$ and conductance produced by the two anion channel inhibitors, BPO-27 and niflumic acid, with no counterbalancing absorption, so ASL depth is predicted to increase (dotted gold line in Fig. 6A) unless MCCV increases. Our evidence shows that MCCV does increase.

Figure 4C–F shows summary plots of $\Delta I_{sc}$ as a function of time and stimulation. Each panel shows responses to 10 µM forskolin or 0.3 µM carbachol for the first 30 min and then the combined agonists for the next 30 min for WT pigs (Fig. 4C,D) and WT ferrets (Fig. 4E,F). Forskolin increased $\Delta I_{sc}$ as expected for both species, but when carbachol was added the $\Delta I_{sc}$ diminished slowly (Fig. 4C,E). Our interpretation of $I_{sc}$ in the forskolin + carbachol condition is that forskolin mainly increased $I_{sc}$ by stimulating anion secretion while carbachol largely decreased $I_{sc}$ by inhibiting $Na^+$ absorption. Inhibiting $Na^+$ absorption would increase net fluid accumulation on
the surface. When carbachol is added first, the ΔIsc decreased directly or after a transient increase (Fig. 4D,F). In both cases the subsequent ΔIsc increase to carbachol + forskolin is smaller than to forskolin alone, because of their opposite effects on Isc but additive effects on ASL depth.

**Figure 4.** Combined agonists inhibit sodium absorption and stimulate anion secretion by surface epithelia. (A) Cartoon of two electrogenic, ion transport pathways across airway apical epithelium: anion secretion increases surface fluid, Na⁺ absorption decreases surface fluid. The two pathways have opposite effects on fluid height, but additive effects on Isc because of their opposite valence and transport directions. (B) Raw trace of Isc across pig tracheal epithelium using Chart 4 software. After reaching a stable, unstimulated Isc (here, > 2 h post-mounting), 10 µM forskolin, 0.3 µM carbachol, 10 µM benzamil, 20 µM benzopyrimido-pyrrolo-oxazinedione (BPO-27) and 200 µM niflumic acid were sequentially added at times shown (see text). (C,D) Pig tracheal mucosa: averaged ΔIsc plots over time in response to (C) forskolin alone followed by forskolin + carbachol and (D) reversed order of agonist addition. (E & F) Ferret tracheal mucosa: averaged ΔIsc plots with same protocol as for pigs. Pig traces (C,D) are based on 10–12 experiments with tissues from 6 to 7 pigs. Ferret traces (E,F) are from 7 experiments with tissues from 5 ferrets.

**Agonist stimulation of human ciliary beat frequency (CBF).** CBF is known to increase in response to elevations of either [Ca²⁺] or [cAMP]. We tested to see if CBF might display synergistic increases to the combined agonists. CBF (in Hz) of unstimulated human nasal cells in KRB (Krebs buffer solution) was 6.79 ± 1.69 at 25 °C and 10.46 ± 0.95 at 37 °C (4 subjects, P = 0.01) (see “Methods” section). As shown in Fig. 5, neither agonist increased CBF significantly, but when combined, their additive effects produced a 27.2% increase to 13.31 ± 0.77 Hz. This was a significant increase compared to unstimulated CBF (n = 4, P < 0.05), but not to the arithmetic sum of ∆CBF to the two agonists: combined agonists: 2.85 ± 0.76, and arithmetic sum: 2.19 ± 0.66
Thus, while increases in CBF will contribute to increases in MCCV, they are unlikely to account for the synergistic increase in MCCV seen with the combined agonists (see "Discussion" section).

**Discussion**

**Main findings.** We have six main findings. (1) Combined agonists produced synergistic increase of MCCV in CF ferrets to 19.95 ± 4.12 mm/min, which is ~55% of MCCV in WT ferrets tested in similar conditions. (2) Little or no airway narrowing was produced by the combined agonists, even in CF ferrets. (3) Pigs also showed synergistic increases in MCCV, so the effect is not species-specific. As for mechanisms, we found: (4) synergistic increases in glandular mucus secretion in pigs, ferrets, and CF ferrets; (5) increased anion secretion and decreased Na+ absorption by surface epithelia; and (6) increased CBF, but only with an additive effect. The magnitude of synergistic MCCV increases were multiple-fold higher than to either agonist alone or to their summed responses and were close to maximal values reported in vivo. In anesthetized ferrets, basal MCCV in vivo was 18.2 ± 1.0 mm/min, and was increased to 32.0 ± 3.8 mm/min with maximal anticholinesterase treatment\(^\text{9}\). In anesthetized pigs, averaged basal MCCV in vivo was ~7 mm/min, and averaged maximal MCCV was ~12 mm/min\(^\text{37}\). If synergy also occurs in vivo, it should help mobilize mucus in certain obstructive airway diseases.

The most significant result was the synergistic increase in MCCV of CF ferrets. This is intriguing because in CF ferret tracheas forskolin alone did not increase MCCV (Fig. 1A) or stimulate gland mucus secretion (Fig. 3H). Also, using a different synergy paradigm human submucosal gland secretion was lost in airways from subjects with CF\(^\text{22}\). Therefore, the combined agonists used in the present study must be activating a CFTR-independent anion secretion pathway that is refractory to forskolin alone (see below).

**Strategies to increase mucus clearance.** Strategies to increase mucus clearance are mainstays of cystic fibrosis treatment but are only modestly effective\(^\text{6-10}\). Pulmozyne (recombinant human DNase), hypertonic
saline, and mannitol all improve mucus clearance in CF, while inhalation of bicarbonate or tromethamine improved CF sputum rheology.

Long before Pulmozyme or hypertonic saline treatments, numerous studies documented that β-adrenergic (cAMP) agonists increased MCC. Indeed β-adrenergic agonists, considered as bronchodilators, are now used ubiquitously for treating obstructive diseases. However, the doses needed to stimulate increased MCC are higher than those that reliably produce bronchodilation, and so it is not clear to what extent the doses presently used are increasing MCC. Unlike β-adrenergic agents, cholinergic (Ca²⁺) agents cause bronchial constriction, which is the basis for the methacholine challenge test, although increased mucus transport in humans by cholinergic stimulation has been reported. Cholinergic agents also stimulate mucus secretion, and it is widely held that mucus over-production contributes to muco-obstructive disease. Thus, it is not surprising that no one has previously advocated a therapeutic use for inhaling an agent that stimulates mucus secretion and causes bronchoconstriction. Indeed, anti-cholinergic agents are used as treatments for COPD, with modest effectiveness apparently resulting primarily from increased bronchodilation. Thus, our finding that a combination of forskolin (or a β-adrenergic, formoterol) and a low-dose cholinergic markedly increased MCC was unexpected.

Our hypothesis is that the combined agonists increase MCC mainly because they increase ASL volume via three processes: synergistic increases in gland mucus secretion, increased fluid secretion and decreased absorption by surface epithelia. The combined agonists produced only modest, additive increases in CBF measured in Krebs solution. It is possible that larger increases in CBF depend on increases in ASL volume, which occurred in the MCCV experiments but not in the CBF experiments. CBF increases have been observed using micro optical coherence tomography (μOCT) to visualize transport in intact tracheas. Importantly, all of this occurs in the absence of airway narrowing.

The concept that MCCV will be faster if ASL depth is increased is supported by studies of patients with pseudohypoaldosteronism (PHA), where loss of function mutations in ENaC subunits eliminate Na⁺ absorption from the airway surface, which more than doubles the volume of ASL and causes a fourfold increase in 0–20 min clearance rates of inhaled tracer from the lungs. Previously, we demonstrated that agonist-induced MCCV in ferrets was doubled when ENaC was inhibited. In those experiments, stimulation with either forskolin or
carbachol in the presence of ENaC inhibition increased MCCV to values similar to those seen with the combined agonists, providing additional evidence that synergistic MCCV results, in part, from ENaC inhibition. The idea that increased ASL provides faster clearance also underlies the logic of using β-agonists and hypertonic saline to increase clearance. It is also supported by studies of ex vivo pig tracheas, where stimulating secretion increased MCCV, blocking secretion slowed MCCV, and blocking absorption increased MCCV of trachea after secretion had been blocked.

Potential molecular and cellular mechanisms. Molecular and cellular mechanisms responsible for synergistic MCCV by β-adrenergic and cholinergic agonists were not addressed in this study, but given our evidence that inhibition of ENaC contributes, prior works on molecular mechanisms of ENaC inhibition are relevant. A common theme is the role of elevated [Ca^{2+}]_{i}, which can be achieved with a wide range of agonists, including ATP, UTP, histamine, thapsigargin, and bradykinin. Cholinergic agonists increase [Ca^{2+}]_{i}; other mechanisms include increasing extracellular antiproteases and other ENaC inhibitors by stimulating secretions from airway glands and surface epithelia.

Because we observed synergistic increases of MCCV and glandular secretion in CF ferrets, mechanisms that bypass CFTR must be involved. Intracellular crosstalk between cAMP and Ca^{2+} signaling pathways via inositol 1,4,5-triphosphate receptor-binding protein release with IP_{3} (IRBIT) has been shown to mediate synergy in salivary gland and pancreatic ducts. Synergistic secretion by lacrimal glands in response to cAMP and cholinergic agonists was partly due to inhibition of p44/p42 mitogen-activated protein kinase (MAPK) by the cAMP agonist CX-4945. A previous study demonstrated that synergistic fluid secretion by cAMP + Ca^{2+} agonists could result from Ca^{2+} release by a cAMP-dependent Ca^{2+} release mechanism in addition to a Ca^{2+} agonist in isolated serous cells from human nasal and WT & CFTR pig tracheal glands. Another study in HEK 293 cells, however, has shown that a cAMP agonist, such as parathyroid hormone or isoproterenol, did not increase [Ca^{2+}]_{i}, but when combined with carbachol, a cAMP agonist potentiated carbachol-induced Ca^{2+} release by unmasking a discrete Ca^{2+} pool in ER. Discrepancies in previous reports might arise in part from using different cell or organ preparations and in part from using different measurement parameters, e.g., [Ca^{2+}]_{i} versus [HCO_{3}^{-}]_{i} ([pHi]). Our earlier studies have shown that there are CFTR-dependent and -independent paths in synergistic glandular mucus secretions, depending on the doses of β-adrenergic and cholinergic agonists.

Potential therapeutic relevance for mucociliary clearance. Procedures to enhance mucociliary clearance are needed for people with muco-obstructive airway disease, including substantial numbers of people with CF. Because β-agonists and methacholine are used routinely (the latter to test for hyperactive airways), little should stand in the way of testing them in combination except that it seems counterintuitive. Our ex vivo data show this combination is effective in speeding mucus clearance without inducing airway narrowing, even in CF animals (Fig. 2), which have airway muscles with increased sensitivity to cholinergic agonists. However, as we found with WT ferrets, the combined agonists minimize/ prevent airway narrowing induced by carbachol in WT pigs and in CF ferret airways. Our results are consistent with an earlier study where greatly reduced bronchoconstriction was observed when a β-adrenergic agonist was administered prior to methacholine in CF children.

It remains to be seen if this combination is safe in individuals with hyperactive airways. If results do warrant further testing in people with CF, it will be important to start early with healthier airways, because the trend observed with β-agonist improvement of MCC was that healthier airways showed more benefit than diseased airways.

Materials and methods
Airway tissue procurement. CF ferret tissues. Seven transgenic CF ferret tracheae (five CFTR^{G551D/G551D}, one CFTR^{G551D/AF508}, one CFTR^{G551D/KO}) were used for MCC assays. These ferrets were raised on the CFTR modulator VX770. Dosing was stopped at least 3 weeks prior to euthanasia; no residual drug effect is expected or was observed (zero response to forskolin). Two CFTR^{G509D} ferret tracheae were used for the tracheal, single gland mucus secretion rate assay. Two CF ferret tracheae (one CFTR^{AF508/AF508} and one CFTR^{G551D/AF508}) ferret tracheae were used for tracheal smooth muscle contraction assay. All isolated CF ferret tracheal trims (2–3 cm in length) were placed in DMEM culture medium immediately after euthanasia and shipped from the University of Iowa via overnight priority express.

Pig tissues. Newborn WT piglet tracheae (2–5 days old) were directly obtained at the swine facility of UC-Davis or from the laboratory of David Stoltz, University of Iowa, via overnight priority express. Postmortem (≤1 h) tracheae from young adult Yorkshire pigs (30–50 kg) and 5–12 months old M. putorius ferrets were from animal facilities at Stanford and Gilroy/CA. All methods using animal tracheae were carried out in accordance with relevant guidelines and regulations of Stanford University and animal protocols were approved (Stanford IACUC protocol#: 10,048). Piglet tracheae were shipped in DMEM cell culture medium, other animal tissues were transported to the laboratory in cold PhysioSol+ solution (Decap, IL/USA) and then transferred to ice-cold Krebs Ringer bicarbonate (KRB) buffer gassed with 95% O_{2} and 5% CO_{2} and kept at 4 °C until use. The KRB buffer contained (in mM): 115 NaCl, 25 NaHCO_{3}, 2.4 K2HPO_{4}, 0.4 KH2PO_{4}, 1.2 MgCl_{2}, 1.2 CaCl_{2}, 10 glucose, and 1.0 μM indomethacin, adjusted to pH 7.2 and ~290 mOsm at room temperature.

Human tissues. Human nasal mucosal tissues were obtained from nasal biopsies during endoscopic sinus surgeries at Yonsei University Hospital. All methods using human tissues were carried out in accordance with relevant guidelines and regulations of Yonsei University, Seoul, South Korea. All experimental protocols were...
agonists was ≥ 10 min instead of 30 min, and it omits the condition in which forskolin was added in addition to carbachol. Each condition was maintained for at least 10 min. Note that this paradigm differs from the following sequence: (1) unstimulated CBF at room temperature; (2) unstimulated at 37 °C; (3) CBF at 37 °C converted to TIFF images. Images were obtained for 10 s at each condition and experiments were performed in high frame-rate digital camera (optiMOS and NIS-Elements microscope imaging software (Nikon, Japan)) and interference contrast (DIC) optics. Images were viewed live and were captured automatically at 2,000 fps with a MATLAB software (MA, USA) was used.

CBF was averaged for each experiment. To analyze captured images and calculate CBF, an in-house coding with ImageJ software (NIH, MD/USA). The appearance of "mucus bubbles" (Supplementary Movie 1) within the oil layer was visualized by oblique illumination and digital images were captured with the macro lens of a Nikon digital camera. Stored images were analyzed by direct measurement or with Imagej software (V. 1.50i, https://imagej.nih.gov/ij/, NIH, MD/USA). Rates for the indicated drugs were calculated for 5 min intervals based on averaging sustained T10-30 secretion rates by 10 μM forskolin or 0.3 μM carbachol alone or T5-30 by the combined agonists to include bubbles to be merged rapidly caused the combined agonists (see Supplementary Movie 1).

Ciliary beat frequency measurement. Ciliary beat frequency was measured using human nasal mucosa in the lab where ferret and pig tracheal mucosa was not readily accessible. Human nasal mucosa from endoscopic nasal biopsies was further dissected under a microscope and placed in a chamber controlled for temperature and pH control. Perfused Krebs bicarbonate buffer was mounted mucosal side up in a 35 mm Petri dish lined with plicable silicone so that the glands were bathed in Krebs buffer while the surface was dried and covered with water-saturated mineral oil. The appearance of "mucus bubbles" (Supplementary Movie 1) within the oil layer was visualized by oblique illumination and digital images were captured with the macro lens of a Nikon digital camera. Stored images were analyzed by direct measurement or with Imagej software (V. 1.50i, https://imagej.nih.gov/ij/, NIH, MD/USA). The other end was attached by 26-gauge wire to a previously calibrated strain gauge (series 400A force transducer system, Cambridge Technology, MA/USA). Tension responses to increasing carbachol doses ± 10 μM forskolin were recorded with a Nikon digital camera and the inner lumen surface area of the tracheal ring was calculated using Imagej (NIH, MD/USA). The other method is using a force transducer. One end of an isolated ferret trachealis muscle bundle was secured in a Sylgard-lined Petri dish filled with KRB solution at 37 °C and pH 7.4. Digital images of tracheal ring contractions in response to agonists for 1–10 min intervals were recorded with a Nikon digital camera and the inner lumen surface area of the tracheal ring was calculated using Imagej (NIH, MD/USA). The other method is using a force transducer. One end of an isolated ferret trachealis muscle bundle was secured in a Sylgard-lined Petri dish filled with KRB solution and the other end was attached by 26-gauge wire to a previously calibrated strain gauge (series 400A force transducer system, Cambridge Technology, MA/USA). Tension responses to increasing carbachol doses ± 10 μM forskolin were obtained and displayed with PowerLab Chart4 software (ADInstruments, CO/USA).

Reagents. Chemicals were purchased from Sigma-Aldrich (St. Louis, MO/USA), Calbiochem (Billerica, MA/USA), and Alomone labs (Jerusalem, Israel). BPO-27 was a generous gift from Alan Verkman, UCSF. Forskolin, benzamil, BPO-27, niflumic acid, formoterol fumarate were dissolved in dimethyl sulfoxide (DMSO) and carbachol was dissolved in sterile double distilled water and indomethacin was dissolved in absolute etha-
nol. Solutions were made fresh or maintained at – 20 °C as aliquots of stock concentration. All chemicals were diluted 1:1000 with bath KRB solution (except indomethacin, 1: 10,000) immediately before use at the concentrations indicated.

### Statistics

Data is presented as mean ± S.E.M. unless otherwise indicated. To compare means of different treatment groups, we used either Student’s paired and unpaired t-test or Mann–Whitney U test.
The authors declare no competing interests.

This study was funded by Cystic Fibrosis Foundation (WINE17G0 to JJW; JOO19G0 to NSJ; and ENGELH08XX0 to JFE), National Institute of Health (R01 HL148184-01 to CEM, R01 DK047967 to JFE), NIH Ferret Resource Center Contract (75N92019C00010 to JFE), and Cystic Fibrosis Research Inc. (NH17-001 to JJW and NSJ).

Author contributions
Conception and design: N.S.J and J.J.W. Acquisition of data: N.S.J, H-J.C., M.S., J.Y.C., C.E.M, and J.J.W. Figure preparation: N.S.J., H-J.C., and J.J.W. Manuscript writing: N.S.J. and J.J.W. All authors reviewed the manuscript.

Funding
This study was funded by Cystic Fibrosis Foundation (WINE17G0 to JJW; JOO19G0 to NSJ; and ENGELH08XX0 to JFE), National Institute of Health (R01 HL148184-01 to CEM, R01 DK047967 to JFE), NIH Ferret Resource Center Contract (75N92019C00010 to JFE), and Cystic Fibrosis Research Inc. (NH17-001 to JJW and NSJ).

Competing interests
The authors declare no competing interests.
